Skip to main content
Home

Epocrates Online Contact us

  • Explore features
  • Reach clinicians
  • Buy now
By vgreene, 1 July, 2021

Monitoring After Tx:<sup>1-3<sup>

By vgreene, 1 July, 2021

Monitoring During Tx:<sup>1-3</sup>

By vgreene, 1 July, 2021

Baseline Eval Before Tx:<sup>1-3</sup>

By vgreene, 1 July, 2021

Monitoring After Tx 1 3

By vgreene, 1 July, 2021

Baseline Eval Before Tx 1 3

By vgreene, 1 July, 2021

Monitoring During Tx 1 3

By vgreene, 1 July, 2021

Baseline Eval Before Tx:<sup>1-4</sup>

By vgreene, 1 July, 2021

Baseline Eval Before Tx 1 4

By vgreene, 1 July, 2021

trastuzumab containing combo agents trastuzumab hyaluronidase pertuzumab trastuzumab hyaluronidase

By vgreene, 1 July, 2021

trastuzumab and its biosimilars trastuzumab anns trastuzumab dkst trastuzumab dttb trastuzumab pkrb trastuzumab qyyp

Pagination

  • First page
  • Previous page
  • …
  • Page 1030
  • Page 1031
  • Page 1032
  • Page 1033
  • Current page 1034
  • Page 1035
  • Page 1036
  • Page 1037
  • Page 1038
  • …
  • Next page
  • Last page

About Us

  • Company Overview
  • Media Relations
  • Contact
  • Editorial Policy
  • Editorial Process
  • Third-Party Sponsorship Policy
  • athenahealth

Products

  • Core Products
  • Mobile CME
  • Product Licenses

Business Solutions

  • Pharma
  • Market Research
  • Institutions

Support

  • Support Center
  • Install
  • My Account

Stay Connected

Facebook Twitter YouTube

Patient Resource Footer Bottom

  • Privacy Policy
  • Terms of Use
  • Site Map